Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18482975
Hou X, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283, 20015-26 18482975
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S80-p - ACC1 (human)
Modsite: LHIRssMsGLHLVkQ SwissProt Entrez-Gene
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso2 (human): S22‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
splitomicin S17834 inhibit treatment-induced increase
S17834 SIRT1 (human) augment treatment-induced increase
resveratrol increase
splitomicin resveratrol inhibit treatment-induced increase
resveratrol SIRT1 (human) augment treatment-induced increase
SIRT1 (human) increase

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose decrease
resveratrol glucose inhibit treatment-induced decrease
resveratrol increase
splitomicin resveratrol inhibit treatment-induced increase
resveratrol SIRT1 (human) augment treatment-induced increase
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
splitomicin S17834 inhibit treatment-induced increase
S17834 SIRT1 (human) augment treatment-induced increase
acadesine increase
LKB1 (human) increase
S17834 LKB1 (human) augment treatment-induced increase
SIRT1 (human) LKB1 (human) augment treatment-induced increase
SIRT1 (human) increase

T172-p - AMPKA2 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose decrease
resveratrol glucose inhibit treatment-induced decrease
resveratrol increase
splitomicin resveratrol inhibit treatment-induced increase
resveratrol SIRT1 (human) augment treatment-induced increase
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
splitomicin S17834 inhibit treatment-induced increase
S17834 SIRT1 (human) augment treatment-induced increase
acadesine increase
LKB1 (human) increase
S17834 LKB1 (human) augment treatment-induced increase
SIRT1 (human) LKB1 (human) augment treatment-induced increase
SIRT1 (human) increase

S428-p - LKB1 (human)
Modsite: SSkIRRLsACkQQ__ SwissProt Entrez-Gene
Orthologous residues
LKB1 (human): S428‑p, LKB1 iso2 (human): , LKB1 (mouse): S431‑p, LKB1 (rat): S431‑p, LKB1 (pig): S339‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
acadesine increase small increase
S17834 increase
resveratrol increase

S79-p - ACC1 (mouse)
Modsite: FHMRSsMsGLHLVKQ SwissProt Entrez-Gene
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso2 (human): S22‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase

T183-p - AMPKA1 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase

T172-p - AMPKA2 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase